The Medicines and Healthcare Products Regulatory Agency (MHRA) took part in an international workshop with other regulators, and has released a statement of intent about how to support the development of drugs for dementia. This work is in support of the World Dementia Council (WDC)’s aim to promote dementia drug development as announced in the G8 Summit’s goal of finding a cure or disease modifying therapy for dementia by 2025.
The meeting in question involved 11 regulators from 10 authorities, and took place in November 2014. The regulators tackled a factual problem statement:
“There is no regulatory solution for the scientific gaps in the understanding of the disease”.
The regulators did at least identify six areas (six high-level constructs relating to research) which may in future assist work towards potential solutions.
MHRA is 1 of 10 regulators to help with the development of treatments for dementia. London: Medicines and Healthcare Products Regulatory Agency / Department of Health / Office for Life Sciences, March 16th 2015.
This relates to:
Regulatory research dementia workshop conclusions. London: Medicines and Healthcare Products Regulatory Agency, March 16th 2015.
Note: Appearance of the above publication(s) was timed to coincide with the World Health Organization (WHO) Ministerial Conference on Global Action Against Dementia, in held in Geneva between March 16th – 17th 2015.